Furthermore, TLR7 agonists such as FDA-approved imiquimod has been used in the treatment of superficial basal cell carcinomas (sBCCs) and dermatological malignancies [34,35], with complete tumor clearance after just 6 weeks of treatment with no recurrence [35]. The gene discussed is TLR7; the disease is basal cell carcinoma.